Flint Animal Cancer Center

VDC-597 for Treatment of Canine Splenic Hemangiosarcoma

Patient Disease:

Canine Splenic Hemangiosarcoma 

Study Name:

VDC-597 for Treatment of Canine Splenic Hemangiosarcoma

Purposes of the study:

  • Canine splenic hemangiosarcoma (HSA) is an aggressive disease, with extremely short survival times when treated with surgery alone

  • VDC-597 is an oral agent which has antitumor and antimetastatic activities in human and mouse cancer models as well as canine HSA cell lines

  • The goal of this study is to evaluate the effectiveness of VDC-597 administered orally to dogs with stage I and II splenic HSA having undergone splenectomy

  • Disease-free time and overall survival times will be evaluated

 Primary Eligibility Criteria:

  • Dogs with a histological diagnosis of HSA of the spleen that has been surgically removed

  • Must start study drug within 21 days of splenectomy

  • No evidence of tumor metastasis

  • Dogs must have good function of liver and kidneys, have acceptable blood cell counts, and be free of severe underlying disease

  • No prior treatment for HSA

Study Protocol:

  • Pre-enrollment: Physical exam, lab work (complete blood count, chemistry profile, urine testing), chest x-rays, abdominal ultrasound

  • Day 0: start treatment , multiple blood sample collections for the first 24 hours

  • Rechecks will be required weekly for the first 2 weeks, every other week through week 8 and every 6 weeks after week 12 for physical exam and lab work (complete blood count, chemistry profile, urinalysis); restaging with chest x-rays and abdominal ultrasound every 6 weeks while on study

  • Dog may continue on treatment until evidence of disease recurrence is found

Owner Responsibilities:

  • The cost of the initial diagnostics to confirm eligibility for enrollment

  • The owner must also fill out a daily log to document VDC-597 administration and side effects

  • The owner is expected to make and keep appointments according to the clinical trial protocol

 Financial Incentives:

  • VDC-597 will be provided at no cost, and all costs associated with performance of the study are covered

  • A $700 credit will be applied to the VTH account at the time of study withdrawal and can be used for additional therapy


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.